Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression [Seeking Alpha]
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: Seeking Alpha
The company has seen impressive results from a phase 3 study of PH94B in patients with social anxiety disorder, leading to a significant increase in stock value. Vistagen Therapeutics is also exploring the potential of PH10, or itruvone, in treating major depressive disorder, with plans for a phase 2b study. I haven't written about Vistagen Therapeutics, Inc. NASDAQ: VTGN ) in five years, but following some interesting results in 2023 from a trial in social anxiety disorder (SAD), the name has come across my radar. In this article, I take Recommended For You Recommended For You About VTGN Stock
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueBusiness Wire
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceBusiness Wire
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Business Wire
- Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish [Seeking Alpha]Seeking Alpha
- Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments [Seeking Alpha]Seeking Alpha
VTGN
Earnings
- 2/13/24 - Beat
VTGN
Sec Filings
- 4/26/24 - Form 8-K
- 4/16/24 - Form DEF
- 4/5/24 - Form PRE
- VTGN's page on the SEC website